Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2006-05-18
2010-12-28
Long, Scott (Department: 1633)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C435S325000, C435S354000, C435S029000
Reexamination Certificate
active
07858843
ABSTRACT:
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
REFERENCES:
patent: 2003/0027281 (2003-02-01), Baker et al.
patent: 2003/0040053 (2003-02-01), Baker et al.
patent: 2003/0215908 (2003-11-01), Ashkenazi et al.
patent: 1 386 931 (2004-02-01), None
Yu et al. J. Biol. Chem. 278:17350-17359; 2003.
Nakae et al (Immunity. 2002; 17:375-387).
Abe et al., “Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages”J Biol Chem. 279 (41) :42605-11 (Oct. 8, 2004).
Abu-Elheiga et al., “Continuous Fatty Acid Oxidation and Reduced Fat Storage in Mice Lacking Acetyl-CoA Carboxylase 2”Science291 (5513) :2613-16 (Mar. 30, 2001).
Adam et al., “Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer”J Biol Chem. 278 (8) :6482-9 (Feb. 21, 2003).
Afar et al., “Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer”Mol Cancer Ther. 3 (8) :921-32 (Aug. 2004).
Alpy et al., “Mentho, a MLN64 homologue devoid of the START domain”J Biol Chem. 277 (52) :50780-7 (Dec. 27, 2002).
Ang et al., “Spatial and temporal expression of Wnt and Dickkopf genes during murine lens development”Gene Expr Patterns. May 2004;4(3):289-95 4 (3) :289-95.
Baeza et al., “Rapid down regulation of pyroglutamyl peptidase II activity by arachidonic acid in primary cultures of adenohypophyseal cells”Life Sci. 68 (17) :2051-60 (Mar. 16, 2001).
Ben-Porath and Benvenisty, “Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteins”Gene183 (1-2) :69-75 (Dec. 12, 1996).
Berditchevski, “Complexes of tetraspanins with integrins: more than meets the eye”J Cell Sci. 114 (Pt 23) :4143-51. (Dec. 2001).
Biunno et al., “Isolation of a pancreas-specific gene located on human chromosome 14q31: expression analysis in human pancreatic ductal carcinomas”Genomics46 (2) :284-6 (Dec. 1, 1997).
Bono et al., “Layilin, a novel integral membrane protein, is a hyaluronan receptor”Mol. Biol. Cell12 (4) :891-900 (2001).
Borowsky and Hynes, “Layilin, a novel talin-binding transmembrane protein homologous with C-type lectins, is localized in membrane ruffles”Cell Biol. 143 (2) :429-42 (Oct. 19, 1998).
Bottcher et al., “The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling”Nature Cell Biology6: 38-44 (2004).
Bouchon et al., “Cutting Edge: Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family”J Immunol. 167 (10) :5517-21 (Nov. 15, 2001).
Bouis et al., “Effects of the CDT6/ANGX gene on tumour growth in immune competent mice”In Vivo. 17 (2) :157-61 (Mar.-Apr. 2003).
Brott and Sokol, “Regulation of Wnt/LRP Signaling by Distinct Domains of Dickkopf Proteins”Molecular&Cellular Biology22 (17) :6100-6110 (Sep. 2002).
Cattaneo et al., “Identification of a region within SEL1L protein required for tumour growth inhibition”Gene326:149-56 (Feb. 4, 2004).
Chalhoub et al., “Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human”Nat Med. 9 (4) :399-406 (Apr. 2003).
Charpantier et al., “Effects of estrogen on global gene expression: identification of novel targets of estrogen action”Cancer Research60 (21) :5977-83 (Nov. 1, 2000).
Chen et al., “cDNA cloning, genomic structure, and chromosome mapping of the human epithelial membrane protein CL-20 gene (EMP1), a member of the PMP22 family”Genomics41 (1) :40-8 (Apr. 1, 1997).
Cheng and Russell, “Mammalian wax biosynthesis. II. Expression cloning of wax synthase cDNAs encoding a member of the acyltransferase enzyme family”J Biol Chem. 279 (36) :37798-807 (Sep. 3, 2004).
Chiaramonte et al., “Notch signal transduction is not regulated by SEL1L in leukaemia and lymphoma cells in culture”Anticancer Res. 22 (6C) :4211-4 (Nov.-Dec. 2002).
Clark et al., “The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment”Genome Research13 (10) :2265-2270 (Oct. 2003).
Colonna et al., “Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells”Eur J Immunol. 30 (2) :697-704 (Feb. 2000).
Coyne et al., “Role of claudin interactions in airway tight junctional permeability”Am J Physiol Lung Cell Mol Physiol. 285 (5) :L1166-78 (Nov. 2003).
Cui et al., “Cloning of human myeloid-associated differentiation marker (MYADM) gene whose expression was up-regulated in NB4 cells induced by all-trans retinoic acid”Mol Biol Rep. 28 (3) :123-38 (2001).
Dail et al., “SHEP1 function in cell migration is impaired by a single amino acid mutation that disrupts association with the scaffolding protein cas but not with Ras GTPases”J Biol Chem. 279 (40) :41892-902 (Oct. 1, 2004).
DeLorey et al., “Mice lacking the β3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavorial characteristics of Angelman syndrome”J Neurosci. 18 (20) :8505-14 (Oct. 15, 1998).
Dgany et al., “Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1”Am J Hum Genet. 71 (6) :1467-74 (Dec. 2002).
Dodelet et al., “A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1A”J Biol Chem. 274 (45) :31941-6 (Nov. 5, 1999).
Doerks et al., “GRAM, a novel domain in glucosyltransferases, myotubularins and other putative membrane-associated proteins”Trends Biochem Sci. 25 (10) :483-5 (Oct. 2000).
Donoviel et al., “Cloning and characterization of Sel-11, a murine homolog of the C. elegans sel-1 gene”Mech Dev. 78 (1-2) :203-7 (Nov. 1998).
Duan et al., “Identification of Human Intestinal Alkaline Sphingomyelinase as a Novel Ecto-enzyme Related to the Nucleotide Phosphodiesterase Family”Journal of Biological Chemistry278 (40) :38528-38536 (2003).
Erne et al., “Rafts in adult peripheral nerve myelin contain major structural myelin proteins and myelin and lymphocyte protein (MAL) and CD59 as specific markers”Neurochem82 (3) :550-62 (Aug. 2002).
Esther et al., “Mice Lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility”Laboratory Investigation74 (5) :953-65 (May 1996).
Ferrante et al., “Molecular and biochemical char
Culbertson Ling Ling
de Sauvage Frederic J.
Montgomery Charles
Shi Zheng-Zheng
Sparks Mary Jean
De Vry Christopher
Dreger Ginger R.
Genentech Inc.
Long Scott
Yeung Bonny
LandOfFree
Gene disruptions, compositions and methods relating thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene disruptions, compositions and methods relating thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene disruptions, compositions and methods relating thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186993